Collegium Pharmaceutical, Inc. Free Cash Flow 2013–2025
Collegium Pharmaceutical, Inc. reported $327.58M of free cash flow for fiscal 2025. That was 61.1% higher than fiscal 2024. Compared with fiscal 2020, the change was +270.6%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $327.58M | +61.1% |
| FY 2024 | $203.33M | -25.9% |
| FY 2023 | $274.29M | +123.7% |
| FY 2022 | $122.61M | +20.7% |
| FY 2021 | $101.61M | +15.0% |
| FY 2020 | $88.40M | +314.1% |
| FY 2019 | $21.34M | -87.0% |
| FY 2018 | $163.91M | +341.0% |
| FY 2017 | $-68.01M | +10.0% |
| FY 2016 | $-75.53M | -244.4% |
| FY 2015 | $-21.93M | -22.1% |
| FY 2014 | $-17.95M | -7.3% |
| FY 2013 | $-16.74M | — |
Source: Collegium Pharmaceutical, Inc. SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open COLL 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Collegium Pharmaceutical, Inc. reported $327.58M of free cash flow for fiscal 2025. That was 61.1% higher than fiscal 2024. Compared with fiscal 2020, the change was +270.6%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Collegium Pharmaceutical, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeCollegium Pharmaceutical, Inc. — frequently asked questions
What is Collegium Pharmaceutical, Inc.'s free cash flow?
Collegium Pharmaceutical, Inc. (COLL) reported free cash flow of $327.58M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Collegium Pharmaceutical, Inc.'s official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.